Project Grant R43DE035019
- The National Institute of Dental and Craniofacial Research (NIDCR) awarded a $294,632 Project Grant under the Oral Diseases and Disorders Research (CFDA 93.121) program to Greenmark Biomedical Inc. in East Lansing, Michigan. The project aims to develop an intraoral imaging system that uses targeted nanoparticle-enhanced fluorescent technology and artificial intelligence (AI) algorithms to improve early detection and monitoring of dental caries (tooth decay). Specifically, the project involves...
- This federal Project Grant award of $297,711.00, provided by the National Institute of Dental and Craniofacial Research (NIDCR) under the Oral Diseases and Disorders Research program (CFDA 93.121), aims to develop and test zinc tetraammine difluoride (ZAF) as a non-invasive, aesthetic, and cost-effective alternative to traditional dental caries management strategies. The objective is to determine the mineral loading efficacy of ZAF agents in human dentin, with the goal of providing ZAF as a...
- The University of Kansas Center for Research Inc. was awarded a $467,008 Project Grant from the National Institute of Dental and Craniofacial Research (NIDCR), under the Oral Diseases and Disorders Research program (CFDA 93.121), to develop a novel non-invasive treatment for dental caries in children and patients with special needs. The project aims to create a biomimetic peptide-polymer interface that works synergistically with silver diamine fluoride (SDF) to arrest caries progression and...
- The National Institute of Dental and Craniofacial Research (NIDCR) awarded a $421,800 Project Grant under the Oral Diseases and Disorders Research program (CFDA 93.121) to Midwestern University. The purpose of this 3-year grant, with a start date of September 7, 2023, is to develop hybrid hydrogel-based dental adhesives that are less vulnerable to hydrolytic degradation compared to current methacrylate-based alternatives. The goal is to create a truly biomimetic dental adhesive that can not only...
- The federal Project Grant award in the amount of $613,736 was provided by the National Institute of Dental and Craniofacial Research (NIDCR), which administers the Oral Diseases and Disorders Research federal grant program (CFDA 93.121). The grant was awarded to Cayman Chemical Co Inc., a for-profit company located in Ann Arbor, Michigan, to develop novel osteogenic small-molecule pharmacotherapies for dental bone regeneration. Specifically, Cayman Chemical will create novel EZH2 inhibitor...
- The National Institute of Dental and Craniofacial Research (NIDCR), under the Oral Diseases and Disorders Research federal grant program (CFDA 93.121), awarded a $298,942 Project Grant to Deltamed LLC on August 20, 2025. The grant funding will support the development of a novel "nanosponge prodrug delivery system" for the small molecule MK2 inhibitors apatinib and MMI-0100. The goal is to improve the circulation half-life and targeted delivery of these compounds to mitigate...
- The National Institute of Dental and Craniofacial Research (NIDCR), under the Oral Diseases and Disorders Research federal grant program (CFDA 93.121), awarded a $422,665 Project Grant to Oregon State University (OSU) to develop an integrated dental plaque bioanalytical platform for point-of-care diagnostics of oral diseases. The project aims to detect and quantify hydrogen peroxide and lactate produced by beneficial and pathogenic oral bacteria, and establish a correlation between oral caries...
- The University of Michigan received a $135,000 Project Grant from the National Institute of Dental and Craniofacial Research (NIDCR) under the Oral Diseases and Disorders Research federal grant program (CFDA 93.121) to develop bioinspired synthetic high-density lipoprotein (SHDL) nanotherapeutics with immunomodulatory and regenerative potential for treating endodontic conditions. The 2-year grant project, which started on August 1, 2025, aims to identify a non-toxic SHDL-antibiotic formulation...
- This $164,255 federal Project Grant award from the National Institute of Dental and Craniofacial Research (NIDCR), under the Oral Diseases and Disorders Research (CFDA 93.121) program, aims to develop innovative methacrylate-based dental materials that can inhibit the formation of microbial biofilms to prevent secondary caries. The key objectives are to: (1) synthesize a new 2-aminoimidazole derivative, H10, and generate a methacrylate-based antimicrobial agent containing covalently conjugated...
- This $322,000 federal Project Grant award from the National Institute of Dental and Craniofacial Research (NIDCR), under the Oral Diseases and Disorders Research program (CFDA 93.121), will support secondary data analysis from the CariesAway study to advance the implementation of school-based oral health programs using silver diamine fluoride (SDF). The research aims to explore the longitudinal caries arrest capabilities of school-based SDF applications, estimate surface-level caries risk...
The National Institute of Dental and Craniofacial Research (NIDCR), under the Oral Diseases and Disorders Research program (CFDA 93.121), awarded a $270,594 Project Grant to Greenmark Biomedical Inc. on Sep 1, 2025. The grant supports the development of nano-fluorapatite particles to directly fill subsurface enamel pores, with the goal of halting the progression of non-cavitated carious lesions without requiring multiple remineralization treatments. Preliminary data demonstrates the ability of these nanoscale fluorapatite particles to penetrate and deliver the biomimetic material into the subsurface of in vitro and ex vivo white spot lesions. The project aims to translate this innovative anticaries therapy into inexpensive over-the-counter products that can treat early-stage lesions from the inside out, stopping their further deterioration. Greenmark Biomedical has also collaborated with the University of Michigan on developing bioresorbable starch-based nanoparticles for delivering minerals and fluoride to early dental lesions, with plans to obtain FDA clearance for transformative dental treatment products.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | $270.6k | 8/29/25 |